Anti-human VEGF receptor Flt-1 monoclonal antibody
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsKenya Shitara, Mikito Ito, Nobuo Hanai
Life of this patent
Estimating the term…
Abstract
The present invention provides a monoclonal antibody which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and a monoclonal antibody which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogensis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid, arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
Claims10
A monoclonal antibody KM1730 belonging to mouse IgG1 subclass produced by hybridoma KM1730 (FERM BP-5697).
A monoclonal antibody KM1731 belonging to mouse IgG2a subclass produced by hybridoma KM1731 (FERM BP-5718).
A monoclonal antibody KM1732 belonging to mouse IgG1 subclass produced by hybridoma KM1732 (FERM BP-5698).
A monoclonal antibody KM1748 belonging to mouse IgG2b subclass produced by hybridoma KM1748 (FERM BP-5699).
A monoclonal antibody KM1750 belonging to mouse IgG2B subclass produced by hybridoma KM1750 (FERM BP-5700).
Dependencies are inferred from the claim text.